Yanai steps down as Teva’s chief executive after four years at the helm
pharmafile | January 3, 2012 | Appointment | Medical Communications | Teva
Shlomo Yanai is to step down as the chief executive and president of Teva, the world’s biggest generic drug makers.
Jeremy Levin, 58, a South African-born pharmaceutical industry executive, has replaced as him the firm’s new head.
Dr Levin was in charge in strategy, alliances and transactions at Bristol-Myers Squibb until the announcement, a role he has filled since 2007.
Levin has more than 25 years of experience in the pharma industry, leading companies and people in the creation, development and delivery of medicines.
Teva said that Yanai is leaving after five years in the company to “move on to a new phase in his career”.
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …






